uBriGene highlights research at Oncolytic conference
October 27, 2024
uBriGene Biosciences Inc. is excited to showcase its cutting-edge research at the 16th Annual International Oncolytic Virotherapy Conference, taking place from October 27-30, 2024, in Rotterdam. As the longest-running and most respected global event in the field, the conference will gather leading scientists, clinicians, and industry experts to discuss the latest advancements in oncolytic virotherapy.
uBriGene will present a poster titled "Amplification of Lister Strain Vaccinia Virus in Human Embryonic Kidney 293XS Cells Cultured in Suspension." This innovative research details a novel method for producing vaccinia virus, a potent viral vector used in vaccines and oncolytic therapies, by leveraging human embryonic kidney (HEK) 293XS cells in suspension. The study highlights serum-free virus production, along with breakthrough strategies to minimize virus aggregation and reduce residual host cell DNA, optimizing the downstream manufacturing process.
Meet the uBriGene experts: uBriGene's professional representatives will be available at the event to discuss this research, answer your questions, and explore opportunities for collaboration. Don't miss the chance to connect with our team and learn how uBriGene’s advanced biomanufacturing services can elevate your projects.
Request uBriGene’s services: Reach out to us during the event to discover how our cutting-edge solutions in viral vector development, cell therapy, and more can accelerate your research and development efforts. We look forward to seeing you in Rotterdam!